REGENXBIO Inc.RGNXNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank42
3Y CAGR-34.4%
5Y CAGR-22.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-34.4%/yr
vs -7.8%/yr prior
5Y CAGR
-22.5%/yr
Recent deceleration
Acceleration
-26.6pp
Decelerating
Percentile
P42
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 9.48% |
| 2024 | -10.22% |
| 2023 | -4.20% |
| 2022 | 33.63% |
| 2021 | 9.11% |
| 2020 | 33.91% |
| 2019 | 48.06% |
| 2018 | 46.57% |
| 2017 | 25.82% |
| 2016 | 163.22% |